←
BioVersys186 posts
BioVersys avatar

BioVersys

@Bioversys

BioVersys is a publicly listed Swiss pharmaceutical company focusing on R&D of small molecules acting on novel bacterial targets.

◷ Joined August 2013▧ 33 Photos and videos
BioVersys avatar
BioVersys@Bioversys·Mar 16

📡 BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start. See: linkedin.com/posts/bioversys… #SavingLivesInResistantTimes #HealthcareInnovation #AMR #biotech #antibiotics #CRAB

Venturelab avatar
⟳ BioVersys retweeted
Venturelab@venturelab_ch·30 Oct 2025

From @ETH lab to @sixgroup Swiss Exchange: the @Bioversys antibiotic revolution 🧬 top100startups.swiss/BioVers… From an ETH Zürich spin-off to a publicly listed biotech tackling antibiotic resistance, BioVersys AG exemplifies how Swiss science can transform global health. With CHF 130 million raised, two WHO-priority drug candidates, and a CHF 213 million valuation on the SIX Swiss Exchange, the company is redefining the future of antibiotics. 💊 🗣️ As Founder & CEO Marc Gitzinger shares: “A world without access to working antibiotics would lead to losing the last 50 years of medical progress.” Supported by @venturekick and Venture Leaders by Venturelab, BioVersys AG’s journey from a PhD project to clinical breakthroughs and global partnerships, shows the power of persistence, precision, and purpose in biotech innovation. 💡 Read how BioVersys is rebuilding the antibiotic pipeline and leading the charge against resistant bacteria. Make sure to follow @venturekick to stay up to date on the latest breakthroughs, and discover the early-stage Swiss startups shaping the future of innovation! #TOP100SSU #SwissStartups #Innovation #Entrepreneurship #StartupEcosystem

Post attachment
BioVersys avatar
BioVersys@Bioversys·10 Nov 2025

🚀More exciting progress and success in funding BioVersys programs - with BV100 Phase 2B to be conducted via Wellcome Funded Trial Network. Link to full press release: bit.ly/43PB1Go

Post attachment
BioVersys avatar
BioVersys@Bioversys·29 Apr 2025

Click lifescievents.com/event/biov… for an informative KOL event; May 7, 2025, 8:30 AM ET / 2:30PM CEST. Featuring Professor David Paterson & Dr. Andrew Shorr, MD, discussing the unmet need & current treatment landscape for carbapenem resistant Acinetobacter baumannii pneumonia. #AMR

Post attachment